Using acetazolamide to treat central sleep apnea in patients with opioid use disorder
Impact of Acetazolamide on Central Sleep Apnea Patients Receiving Medication for Opioid Use Disorder
PHASE2 · University of Pittsburgh · NCT06521476
This study is testing if the medication acetazolamide can help people with central sleep apnea who are being treated for opioid use disorder feel better and improve their sleep quality.
Quick facts
| Phase | PHASE2 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | University of Pittsburgh (other) |
| Locations | 1 site (Pittsburgh, Pennsylvania) |
| Trial ID | NCT06521476 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effects of acetazolamide on patients with central sleep apnea (CSA) who are being treated for opioid use disorder with medications like methadone or buprenorphine. Participants will be randomized to receive either acetazolamide or a placebo for seven days, followed by an overnight sleep study to evaluate changes in breathing, sleep quality, and various physiological measures. The study aims to determine if acetazolamide can alleviate CSA symptoms and lead to improvements in anxiety, cognition, and drug cravings. By understanding the relationship between CSA and opioid use disorder, the trial seeks to identify potential therapeutic benefits of acetazolamide in this population.
Who should consider this trial
Good fit: Ideal candidates are patients on medication for opioid use disorder who also have central sleep apnea.
Not a fit: Patients with sleep-related hypoventilation or other causes of central sleep apnea may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could improve sleep quality and reduce drug cravings in patients with opioid use disorder.
How similar studies have performed: While the specific combination of acetazolamide and opioid use disorder is novel, previous studies have shown acetazolamide to be effective in treating central sleep apnea in other contexts.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients on Medication for Opioid Use Disorder (MOUD) with central sleep apnea. Exclusion Criteria: * Sleep-related Hypoventilation. * Other causes of Central Sleep Apnea besides Opioid Use. * Pregnancy. * Contraindications for Acetazolamide.
Where this trial is running
Pittsburgh, Pennsylvania
- University of Pittsburgh — Pittsburgh, Pennsylvania, United States (RECRUITING)
Study contacts
- Principal investigator: Sanjay R Patel, MD — University of Pittsburgh
- Study coordinator: Elizabeth Stempkowski
- Email: stempkowskiem@upmc.edu
- Phone: 412-648-9507
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Central Sleep Apnea Comorbid With Opioid Use, Acetazolamide, Opioid Use Disorder, Medication for opioid use disorder, Methadone, Buprenorphine